Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, have announced the signing of Memorandum of Understanding (MOU) , which will see the two organizations collaborating on establishing and strengthening CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities.

Under the MOU, the partnership will prioritize the development and large-scale manufacturing of high-quality lentiviral vectors, a critical component in CAR T-cell therapies for leukemia and other blood cancers. Porton Advanced will leverage its expertise in viral vector and CAR-T cell therapy process development and manufacturing to support EVA Pharma's efforts to deliver safe, effective, and scalable treatments. The collaboration brings together Porton Advanced' s cutting-edge expertise in viral vector and cell therapy manufacturing with EVA Pharma's growing footprint in high-tech biopharmaceuticals and its established regional infrastructure and market leadership across the Middle East and Africa. This will support technology transfer and local production capabilities for innovative cancer therapies while ensuring the highest quality standards.

"Patients battling cancer deserve more than hope; they deserve access to innovations once thought out of reach." said Riad Armanious, CEO of EVA Pharma. "Together EVA Pharma and Porton Advanced are combining our capabilities to localize innovation, at scale and with equity."

"We are excited to collaborate with EVA Pharma to make transformative cell therapies more accessible," said Andrew Chen, CFO of Porton Advanced. "This partnership marks a sustainable model for advanced therapy manufacturing in emerging markets. This collaboration aligns with our vision of supporting cutting-edge treatments globally accessible and further validates Porton Advanced' s unique value in facilitating global advanced therapy pipelines".

The agreement aligns with global efforts to expand access to advanced immunotherapies, particularly in markets with limited cell and gene therapy infrastructure. By establishing localized production hubs in Egypt and Saudi Arabia, the partnership aims to reduce costs, shorten treatment timelines, and set new standards for oncology care in the MEA region.